What is DefiniGEN?
DefiniGEN specializes in providing advanced human-derived induced pluripotent stem cell (iPSC) disease modeling services, focusing on metabolic and rare diseases. Their comprehensive offerings include efficacy and toxicology screening, gene editing services, and a diverse portfolio of disease models, such as those for MASLD and Wilson's Disease. Serving a global clientele of leading pharmaceutical companies, biotechnology firms, and research institutions, DefiniGEN leverages over 13 years of proprietary iPSC technology expertise to deliver scalable and predictive liver and metabolic disease models, thereby accelerating scientific discovery.
How much funding has DefiniGEN raised?
DefiniGEN has raised a total of $6.1M across 2 funding rounds:
Series A
$3.8M
Private Equity
$2.3M
Series A (2014): $3.8M with participation from 24 Haymarket and Cambridge Enterprise
Private Equity (2016): $2.3M led by Cambridge Enterprise
Key Investors in DefiniGEN
Cambridge Enterprise
Cambridge Enterprise is the commercialization arm of the University of Cambridge, investing in and supporting spin-out companies and academic innovation. Their focus is on translating cutting-edge research into impactful commercial ventures.
24 Haymarket
24 Haymarket is a private network of investors and operators dedicated to providing capital and strategic support to promising ventures. They partner with entrepreneurs to foster growth and innovation across various sectors.
What's next for DefiniGEN?
The recent major strategic investment signals a new phase of growth and development for DefiniGEN. This capital infusion is expected to fuel further innovation in their iPSC technology, expand their disease model catalog, and enhance their service capabilities for clients in the pharmaceutical and biotech industries. The company's focus on critical areas like metabolic and rare diseases positions it for significant impact in drug discovery and development, with this latest backing likely enabling broader market penetration and deeper research collaborations.
See full DefiniGEN company page
